An ADC based on an anti-STn antibody conjugated to antineoplastic drug monomethyl auristatin E (MMAE) eliminated STn+ ovarian cancer cells in vitro and reduced the tumor volume by the depletion of STn+ CSCs in an ovarian tumor xenograft model [118]. The gene discussed is EEF1A2; the disease is ovarian neoplasm.